<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2016.4981</article-id>
<article-id pub-id-type="publisher-id">mmr-13-04-3639</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Glycyrrhizic acid prevents enteritis through reduction of NF-&#x003BA;B p65 and p38MAPK expression in rat</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>YI-MING</given-names></name></contrib>
<contrib contrib-type="author">
<name><surname>DU</surname><given-names>GUO-QIANG</given-names></name><xref ref-type="corresp" rid="c1-mmr-13-04-3639"/></contrib>
<aff id="af1-mmr-13-04-3639">Department of Pediatric Surgery, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China</aff></contrib-group>
<author-notes>
<corresp id="c1-mmr-13-04-3639">Correspondence to: Mr. Guo-Qiang Du, Department of Pediatric Surgery, Linyi People's Hospital, 27 Jiefang Road, Linyi, Shandong 276003, P.R. China, E-mail: <email>dudoctordgq@163.com</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>04</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>03</month>
<year>2016</year></pub-date>
<volume>13</volume>
<issue>4</issue>
<fpage>3639</fpage>
<lpage>3646</lpage>
<history>
<date date-type="received">
<day>06</day>
<month>05</month>
<year>2015</year></date>
<date date-type="accepted">
<day>07</day>
<month>01</month>
<year>2016</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2016, Spandidos Publications</copyright-statement>
<copyright-year>2016</copyright-year></permissions>
<abstract>
<p>Glycyrrhizic acid has a variety of biological properties, including a protective function in the liver, and anti-inflammatory, anti-ulcer, anti-anaphylaxis, anti-oxidant, immunoregulatory, antiviral and anticancer activities. The efficacy of glycyrrhizic acid can be increased when combined with other medicines. In the present study, the potential protective effects of glycyrrhizic acid against enteritis in rats, and its role in regulating anti-inflammation, anti-oxidation, angiogenic and apoptotic mechanisms were investigated using enzyme-linked immunosorbent and bicinchoninic acid assays, and reverse transcription-quantitative polymerase chain reaction and western blotting analyses. Adult male Sprague-Dawley rats were injected with 20 mg/kg methotrexate (MTX) to establish enteritis. Additionally, rats with MTX-induced enteritis were peritoneally injected with 200 mg glycyrrhizic acid for 9 weeks. The current study demonstrated that glycyrrhizic acid could alleviate MTX-induced increases of tumor necrosis factor-&#x003B1;, interleukin (IL)-1&#x003B2; and IL-6 levels, and raise IL-10 levels, in rats with enteritis. Treatment with glycyrrhizic acid significantly reduced D-lactate and intercellular adhesion molecule-1 gene expression (P&lt;0.01), but did not inhibit diamine oxidase activity in MTX-induced enteritis. Pretreatment with glycyrrhizic acid significantly suppressed the promotion of p38 mitogen-activated protein kinase (p38MAPK), nuclear factor-&#x003BA;B p65 (NF-&#x003BA;B p65) protein expression, interferon-&#x003B3; protein concentration, and caspase-3 and cycloxygenase-2 activity in MTX-induced enteritis (P&lt;0.01). The findings of the current study suggest that glycyrrhizic acid may prevent enteritis by reducing NF-&#x003BA;B p65 and p38MAPK expression levels, which may inform future therapeutic strategies for the treatment of enteritis.</p></abstract>
<kwd-group>
<kwd>glycyrrhizic acid</kwd>
<kwd>enteritis</kwd>
<kwd>nuclear factor-&#x003BA;B p65</kwd>
<kwd>p38 mitogen-activated protein kinase</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>The intestinal mucosa is the major location of nutrient digestion and absorption, as well as the primary gateway for invasion by pathogenic microorganisms and their toxins (<xref rid="b1-mmr-13-04-3639" ref-type="bibr">1</xref>). Under physiological conditions, extra-intestinal tissues and organs are effectively protected from pathogenic microorganisms and their toxins by the intestinal mucosa barrier (IMB) (<xref rid="b2-mmr-13-04-3639" ref-type="bibr">2</xref>). The afore-mentioned mechanism involves the IMB, intestinal mucosa immune barrier, micropopulation barrier, chemical barrier, slime layer and aqueous layer (<xref rid="b3-mmr-13-04-3639" ref-type="bibr">3</xref>). As a result, when the IMB is damaged, microorganisms and their toxins can move through the IMB, and enter the portal vein and lymphatic system, leading to bacterial translocation, potentially causing systemic inflammatory response syndrome and multiple organ dysfunction syndrome (<xref rid="b4-mmr-13-04-3639" ref-type="bibr">4</xref>).</p>
<p>Dysfunction of the IMB is closely associated with diseases of the digestive system. Numerous factors, including intestinal infection, inflammation and mechanical damage, can induce abnormal IMB function (<xref rid="b5-mmr-13-04-3639" ref-type="bibr">5</xref>). IMB dysfunction increases intestinal mucosa permeability, causing bacteria and antigens to be translocated from the enteric cavity to the lamina propria mucosae, resulting in the activation of immune cells and an abnormal mucosal immune response (<xref rid="b6-mmr-13-04-3639" ref-type="bibr">6</xref>). Inflammatory bowel diseases, such as enteritis, can also damage the IMB by increasing the release of inflammatory cytokines, further exacerbating the abnormal mucosal immune response (<xref rid="b7-mmr-13-04-3639" ref-type="bibr">7</xref>). It is widely understood that IMB dysfunction causes the molecular pathogenesis of enteritis (<xref rid="b7-mmr-13-04-3639" ref-type="bibr">7</xref>,<xref rid="b8-mmr-13-04-3639" ref-type="bibr">8</xref>).</p>
<p><italic>Glycyrrhiza</italic>, a group of perennial leguminous grasses, have been used in traditional medicine in Asian countries, including China, India and Japan, for thousands of years, and are now widely used in Europe and the Middle East (<xref rid="b9-mmr-13-04-3639" ref-type="bibr">9</xref>). Glycyrrhizic acid is water-soluble compound, consisting of two molecules of glucuronic acid and one molecule of glycyrrhetinic acid (<xref rid="b10-mmr-13-04-3639" ref-type="bibr">10</xref>). Glycyrrhizic acid, which exhibits a series of effects, such as liver protection and membrane stabilization, is one of the major constituents of <italic>Glycyrrhiza</italic> root extract. Its biological effects include anti-inflammatory, anti-ulcer, anti-anaphylaxis, anti-oxidant, immunoregulatory, membrane stabilization, antiviral and anticancer activities, as well as liver protective properties (<xref rid="b9-mmr-13-04-3639" ref-type="bibr">9</xref>,<xref rid="b10-mmr-13-04-3639" ref-type="bibr">10</xref>). The pentacyclic triterpene structure in glycyrrhetinic acid gives glycyrrhizic acid a similar structure to glucocorticoids and, as such, similar anti-inflammatory effects (<xref rid="b11-mmr-13-04-3639" ref-type="bibr">11</xref>). The anti-inflammatory effect of glycyrrhizic acid does not cause severe adverse reactions, therefore, it is widely used in the treatment of acute and chronic hepatitis, bronchitis, acquired immune deficiency syndrome and other diseases (<xref rid="b12-mmr-13-04-3639" ref-type="bibr">12</xref>,<xref rid="b13-mmr-13-04-3639" ref-type="bibr">13</xref>).</p>
<p>Nuclear factor (NF)-&#x003BA;B p65 is a common transcription factor which is activated by inflammatory cytokines, growth factor or chemokines in order to regulate transcription (<xref rid="b14-mmr-13-04-3639" ref-type="bibr">14</xref>). Following stimulation by an inflammatory cytokine or various cytokines, a trimer of NF-&#x003BA;B and I&#x003BA;Ba dissociates in the cytoplasm, and phosphorylation of I&#x003BA;Ba facilitates nuclear localization to induce NF-&#x003BA;B expression, which is a classical NF-&#x003BA;B pathway (<xref rid="b15-mmr-13-04-3639" ref-type="bibr">15</xref>). Following nuclear entry, NF-&#x003BA;B can regulate gene expression. Positive and negative feedback loops and subsequent inflammatory reactions further affect the inflammatory reaction of the body (<xref rid="b16-mmr-13-04-3639" ref-type="bibr">16</xref>).</p>
<p>Mitogen activated protein kinase (MAPK) signal transduction pathways are associated with cell proliferation, differentiation, cell apoptosis and angiogenesis (<xref rid="b17-mmr-13-04-3639" ref-type="bibr">17</xref>). In particular, the p38MAPK signal transduction pathway regulates stress responses, such as inflammation and cell apoptosis (<xref rid="b18-mmr-13-04-3639" ref-type="bibr">18</xref>). Following the activation of MAPK pathways by lipopolysaccharides and other factors, numerous inflammatory mediators are generated via complex signal conduction pathways, which promote inflammation. p38MAPK can be activated by various stimulus along diversified transduction pathways which activate numerous transcription factors and mediate a range of biological effects (<xref rid="b19-mmr-13-04-3639" ref-type="bibr">19</xref>).</p>
<p>The present study aimed to investigate the mechanism by which glycyrrhizic acid prevents enteritis in rats and whether its effects are mediated via reduction of NF-&#x003BA;B p65 and p38MAPK expression levels.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Chemicals</title>
<p>Methotrexate (MTX) was purchased from Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd. (Shanghai, China). Tumor necrosis factor-&#x003B1; (TNF-&#x003B1;; MTA00), interleukin-1&#x003B2; (IL-1&#x003B2;; DLB50), IL-6 (D6050), IL-10 (D1000B), cycloxy-genase-2 (COX-2; KCB4198) and interferon-&#x003B3; (IFN-&#x003B3;; RIF00) enzyme-linked immunosorbent assay (ELISA) kits were purchased from R&amp;D Systems Europe, Ltd. (Abingdon, UK). Bicinchoninic acid (BCA) assay kit (P0010S) was purchased from Beyotime Institute of Biotechnology (Jiangsu, China).</p></sec>
<sec>
<title>MTX-induced enteritis rat model and grouping</title>
<p>A total of 24 adult male Sprague-Dawley rats, aged 6&#x02013;7 weeks and weighing 220&#x02013;250 g, were obtained from the Animal Resource Center of the Linyi People's Hospital (Linyi, China). Rats were housed at an ambient temperature of 22&#x000B1;1&#x000B0;C, with a 12-h light-dark cycle, and free access to food and water. The current study was conducted in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health (<xref rid="b20-mmr-13-04-3639" ref-type="bibr">20</xref>) and the protocol was approved by the Ethics Committee of Linyi People's Hospital. The experimental rats were randomly allocated into three equal groups: Control, MTX and glycyrrhizic acid groups (n=8 per group). In the control group, normal rats were peritoneally injected with 1 ml normal saline. In the MTX and glycyrrhizic acid groups, enteritis was induced in rats by injection with 20 mg/kg MTX. In the MTX group, MTX-induced rats were peritoneally injected with 1 ml normal saline. In the glycyrrhizic acid group, MTX-induced rats were peritoneally injected with 200 mg glycyrrhizic acid for 9 weeks (<xref rid="b21-mmr-13-04-3639" ref-type="bibr">21</xref>). After 9 weeks, rats was sacrificed via decollation and blood samples and intestinal tissue samples were subsequently harvested. Blood samples were centrifuged at 13,200 &#x000D7; g for 10 min at 4&#x000B0;C to obtain the serum. Serum and intestinal tissue samples were stored at &#x02212;80&#x000B0;C prior to analysis.</p></sec>
<sec>
<title>Collection of rat blood samples and measurement of inflammatory mediators by ELISA</title>
<p>Peripheral blood was collected after glycyrrhizic acid treatment and centrifuged at 13,200 &#x000D7; g for 10 min at 4&#x000B0;C. The supernatant was collected, and the levels of TNF-&#x003B1;, IL-1&#x003B2;, IL-6, IL-10, IFN-&#x003B3; and COX-2 were measured using the described ELISA kits, according to the manufacturer's protocol.</p></sec>
<sec>
<title>Measurement of plasma D-lactate concentration and diamine oxidase (DAO) activity</title>
<p>Peripheral blood supernatant was obtained as described for the ELISAs. The D-lactate concentration levels and DAO activity were measured using spectrophotometry (Multiskan MS plate reader; Thermo Fisher Scientific, Inc., Waltham, MA, USA), as previously described (<xref rid="b22-mmr-13-04-3639" ref-type="bibr">22</xref>,<xref rid="b23-mmr-13-04-3639" ref-type="bibr">23</xref>).</p></sec>
<sec>
<title>Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) of intercellular adhesion molecule-1 (ICAM-1)</title>
<p>Total RNA was extracted from rat intestinal tissue samples using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The extracted RNA (1 <italic>&#x000B5;</italic>g) was reverse transcribed into cDNA using a SuperScript III First-Strand Synthesis system (Invitrogen; Thermo Fisher Scientific, Inc.). qPCR was performed on a Gene Amp 2400 PCR system (PerkinElmer, Inc., Waltham, MA, USA) using a Premix <italic>Ex Taq</italic> kit (Takara Bio, Inc., Kyoto, Japan), according to the manufacturer's protocol as follows: 94&#x000B0;C for 5 min followed by 40 cycles of 95&#x000B0;C for 30 sec, 60&#x000B0;C for 45 sec and 72&#x000B0;C for 30 sec, and 72&#x000B0;C for 10 min. Primer sequences were as follows: ICAM-1 forward 5&#x02032;-AACGACGCTTCTTTTGCTC-3&#x02032; and reverse 5&#x02032;-CTCTGGCGGTAATAGGTGTAA-3&#x02032;; and GAPDH (reference) forward 5&#x02032;-CGTGTTCCTACCCCCAATGT-3&#x02032; and reverse 5&#x02032;-TGTCATACTTGGCAGGTTTCT-3&#x02032;. Relative expression levels were normalized against GAPDH, using the 2<sup>&#x02212;&#x00394;&#x00394;Cq</sup> method (<xref rid="b24-mmr-13-04-3639" ref-type="bibr">24</xref>).</p></sec>
<sec>
<title>Western blotting</title>
<p>Intestinal tissue samples were collected and incubated with 100 <italic>&#x000B5;</italic>l tissue lysis buffer (Beyotime Institute of Biotechnology) for 30 min on ice. Homogenates were centrifuged at 13,200 &#x000D7; g for 10 min at 4&#x000B0;C, the supernatant was collected and the protein concentration measured using a the BCA kit, according to the manufacturer's protocol. Equal concentrations of protein sample were separated by running on 10% SDS-PAGE gels (Beijing Solarbio Science &amp; Technology Co., Ltd., Beijing, China) at 100 V for 75 min and transferred onto polyvinylidene difluoride membranes (0.22 mm; Bio-Rad Laboratories, Inc., Munich, Germany). The membrane was incubated with anti-NF-&#x003BA;B-p65 (sc-372; 1,2,000), rabbit polyclonal anti-phosphorylated (p)-p38MAPK (sc-101758), anti-p38MAPK (sc-728), rabbit polyclonal anti-iNOS (sc-651; all 1:1,000) or &#x003B2;-actin (1:2,000; sc-130656; all Santa Cruz Biotechnology, Inc., Dallas, TX, USA) primary antibodies overnight at 4&#x000B0;C. Membranes were then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (sc-2370; 1:2,000; Santa Cruz Biotechnology, Inc.) and enhanced chemiluminescence kit (GE Healthcare Life Sciences, Chalfont, UK). The relative protein expression was determined using a Gel Dox 1000 fluorescent image analysis system (Bio-Rad Laboratories, Inc.).</p></sec>
<sec>
<title>Caspase-3 activity</title>
<p>Protein was extracted from intestinal tissue samples, as described for western blotting, and quantified using the BCA assay kit, according to the manufacturer's protocol. Equal concentrations of protein were incubated with Ac-DEVD-pNA (Beyotime Institute of Biotechnology) at 37&#x000B0;C for 2 h in the dark, as previously described (<xref rid="b25-mmr-13-04-3639" ref-type="bibr">25</xref>), and the absorbance at 405 nm was measured using a Varioskan Flash spectral scanning multimode reader.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Data from the individual groups were presented as the mean &#x000B1; standard deviation and were analyzed using analysis of variance followed by Tukey-Kramer multiple comparisons test. Statistical analyses were performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL&lt; USA). P&lt;0.05 was considered to indicate a statistically significant difference.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Glycyrrhizic acid alters the expression of inflammatory factors in rat enteritis</title>
<p>The chemical structure of glycyrrhizic acid (95.0%; Sigma-Aldrich, St. Louis, MO, USA) is presented in <xref rid="f1-mmr-13-04-3639" ref-type="fig">Fig. 1</xref>. The current study examined the effect of glycyrrhizic acid on the levels of several inflammatory factors in a rat model of enteritis. The protein concentration levels of TNF-&#x003B1;, IL-1&#x003B2; and IL-6 were significantly increased in rats with MTX-induced enteritis compared with the control group (P&lt;0.01; <xref rid="f2-mmr-13-04-3639" ref-type="fig">Fig. 2A&#x02013;C</xref>). Pretreatment with glycyrrhizic acid significantly alleviated the increase of TNF-&#x003B1;, IL-1&#x003B2; and IL-6 resulting from MTX-induced enteritis (P&lt;0.01; <xref rid="f2-mmr-13-04-3639" ref-type="fig">Fig. 2A&#x02013;C</xref>). Conversely, IL-10 levels were significantly reduced in rats with MTX-induced enteritis compared with the control group (P&lt;0.01; <xref rid="f2-mmr-13-04-3639" ref-type="fig">Fig. 2D</xref>), and glycyrrhizic acid treatment significantly raised the IL-10 levels compared with the MTX group (P&lt;0.01; <xref rid="f2-mmr-13-04-3639" ref-type="fig">Fig. 2D</xref>).</p></sec>
<sec>
<title>D-lactate concentration levels and DAO activity are increased by glycyrrhizic acid in rat enteritis</title>
<p>The current study probed whether glycyrrhizic acid prevents D-lactate and DAO changes that occur in rat enteritis. The D-lactate concentration and DAO activity were significantly increased in MTX-induced enteritis compared with control group (P&lt;0.01; <xref rid="f3-mmr-13-04-3639" ref-type="fig">Fig. 3</xref>). Furthermore, treatment with glycyrrhizic acid significantly reduced the D-lactate concentration levels compared with the MTX group (P&lt;0.01), however, glycyrrhizic acid did not inhibit the increased DAO activity in MTX-induced enteritis (<xref rid="f3-mmr-13-04-3639" ref-type="fig">Fig. 3B</xref>).</p></sec>
<sec>
<title>ICAM-1 expression is reduced by glycyrrhizic acid in rat enteritis</title>
<p>As presented in <xref rid="f4-mmr-13-04-3639" ref-type="fig">Fig. 4</xref>, ICAM-1 mRNA expression was significantly higher in MTX-induced enteritis compared with expression in control rats (P&lt;0.01). However, administration of glycyrrhizic acid significantly reduced the ICAM-1 gene expression compared with MTX-induced enteritis rats (P&lt;0.01; <xref rid="f4-mmr-13-04-3639" ref-type="fig">Fig. 4</xref>).</p></sec>
<sec>
<title>Increase of NF-&#x003BA;B-p65 protein expression in enteritis is prevented by glycyrrhizic acid in rat enteritis</title>
<p>As shown in <xref rid="f5-mmr-13-04-3639" ref-type="fig">Fig. 5</xref>, MTX-induced enteritis resulted in significantly increased NF-&#x003BA;B-p65 expression compared with the control group (P&lt;0.01). As expected, glycyrrhizic acid significantly suppressed the MTX-induced increase in NF-&#x003BA;B-p65 expression (P&lt;0.01; <xref rid="f5-mmr-13-04-3639" ref-type="fig">Fig. 5</xref>).</p></sec>
<sec>
<title>Glycyrrhizic acid prevents increase in IFN-&#x003B3; concentration levels in rat enteritis</title>
<p>There was a significant increase IFN-&#x003B3; levels in rats with MTX-induced enteritis compared with the control rats (P&lt;0.01; <xref rid="f6-mmr-13-04-3639" ref-type="fig">Fig. 6</xref>). As presented in <xref rid="f6-mmr-13-04-3639" ref-type="fig">Fig. 6</xref>, glycyrrhizic acid treatment prevented the promotion of IFN-&#x003B3; levels observed in the MTX group (P&lt;0.01).</p></sec>
<sec>
<title>Glycyrrhizic acid reduces caspase-3 activity in rat enteritis</title>
<p>To understand the underlying mechanism of glycyrrhizic-mediated anti-apoptosis, the present study examined whether glycyrrhizic acid could inhibit caspase-3 activity in an MTX-induced enteritis model. As presented in <xref rid="f7-mmr-13-04-3639" ref-type="fig">Fig. 7</xref>, rats in the MTX group exhibited significantly increased caspase-3 activity compared with control group (P&lt;0.01). However, the elevation of caspase-3 activity was significantly inhibited by treatment with glycyrrhizic acid compared with the MTX group (P&lt;0.01; <xref rid="f7-mmr-13-04-3639" ref-type="fig">Fig. 7</xref>).</p></sec>
<sec>
<title>Glycyrrhizic acid prevents iNOS protein expression in rat enteritis</title>
<p>To examine the underlying mechanisms of glycyrrhizic-mediated changes in nitric oxide (NO) levels, the current study examined whether glycyrrhizic acid inhibits iNOS protein expression in the MTX-induced enteritis rat model. As presented in <xref rid="f8-mmr-13-04-3639" ref-type="fig">Fig. 8</xref>, the iNOS protein expression was significantly elevated in MTX-induced enteritis compared with the control group (P&lt;0.01). However, treatment with glycyrrhizic acid reduced the increase of iNOS protein expression, as compared with the MTX-induced enteritis rats (<xref rid="f8-mmr-13-04-3639" ref-type="fig">Fig. 8</xref>).</p></sec>
<sec>
<title>Glycyrrhizic acid inhibits COX-2 activity in rat enteritis</title>
<p>To investigate the mechanism by which the anti-oxidant effects of glycyrrhizic acid are mediated, the present study examined the influence of glycyrrhizic acid on COX-2 activity. Compared with the control group, the COX-2 activity was significantly increased in rats with MTX-induced enteritis (P&lt;0.01; <xref rid="f9-mmr-13-04-3639" ref-type="fig">Fig. 9</xref>). This increase was significantly attenuated by glycyrrhizic acid treatment compared with the MTX group (P&lt;0.01; <xref rid="f9-mmr-13-04-3639" ref-type="fig">Fig. 9</xref>).</p></sec>
<sec>
<title>Glycyrrhizic acid prevents p38MAPK expression in rat enteritis</title>
<p>To examine the effects of glycyrrhizic acid on the MAPK signaling pathway, the protein expression levels of total and p-p38MAPK, a key mediator of MAPK signaling, were measured using western blotting. The present study observed that the p38MAPK protein expression was significantly increased in MTX-induced enteritis compared with the control group (P&lt;0.01; <xref rid="f10-mmr-13-04-3639" ref-type="fig">Fig. 10</xref>). However, treatment with glycyrrhizic acid significantly attenuated the increase in p38MAPK protein expression observed in the MTX group (P&lt;0.01; <xref rid="f10-mmr-13-04-3639" ref-type="fig">Fig. 10</xref>).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>IMB dysfunction is closely associated with the paroxysm of enteritis. IMB dysfunction, induced by psychological stress, intestinal infection, mechanical injury and other factors, can increase intestinal mucosa permeability (<xref rid="b1-mmr-13-04-3639" ref-type="bibr">1</xref>,<xref rid="b2-mmr-13-04-3639" ref-type="bibr">2</xref>). Increased mucosa permeability contributes to the translocation of bacteria and antigens from the enteric cavity to the lamina propria mucosae, resulting in activation of immune cells and an abnormal mucosa immune response (<xref rid="b26-mmr-13-04-3639" ref-type="bibr">26</xref>). Additionally, damaging factors are present during the enteritis paroxysm, which can further injure the IMB and aggravate the abnormal mucosa immune response (<xref rid="b26-mmr-13-04-3639" ref-type="bibr">26</xref>). Drugs for the treatment of enteritis can reduce intestinal mucosal inflammation and regulate IMB function (<xref rid="b27-mmr-13-04-3639" ref-type="bibr">27</xref>). IMB function is one of the therapeutic targets in the treatment of enteritis and is an important area of investigation within enteritis pathophysiology research (<xref rid="b26-mmr-13-04-3639" ref-type="bibr">26</xref>,<xref rid="b27-mmr-13-04-3639" ref-type="bibr">27</xref>). The current study observed that pretreatment with glycyrrhizic acid significantly suppressed the concentration levels of various inflammatory mediators that had been increased in MTX-induced enteritis, including TNF-&#x003B1;, IL-1&#x003B2;, IL-6 and D-lactate levels, whereas, IL-10 levels were reduced in enteritis and increased by glycyrrhizic acid. Bhattacharjee <italic>et al</italic> (<xref rid="b28-mmr-13-04-3639" ref-type="bibr">28</xref>) demonstrated that glycyrrhizic acid suppresses inflammatory responses and protects against <italic>Leishmania</italic> parasites within the host. Orazizadeh <italic>et al</italic> (<xref rid="b29-mmr-13-04-3639" ref-type="bibr">29</xref>) observed that glycyrrhizic acid protects against nanoparticle-induced hepatotoxicity through anti-inflammatory mechanisms, and suggested that glycyrrhizic acid may be a novel candidate for research and development of enteritis therapeutics.</p>
<p>ICAM-1 is expressed on the membrane of endothelial cells, white blood cells (WBC) and enterocytes of intestinal tissues, acting as a receptor for &#x003B2;2-integrin present on WBCs. Therefore, ICAM-1 is important in leukocyte movement and aggregation during enteritis (<xref rid="b30-mmr-13-04-3639" ref-type="bibr">30</xref>). Enteritis also induces the expression of adhesion molecules, including ICAM-1 (<xref rid="b31-mmr-13-04-3639" ref-type="bibr">31</xref>). During the acute phase of enteritis, expression of ICAM-1 on the surface of activated vascular endothelial cells is markedly increased, while the mortality of ICAM-1-deficient mice is markedly reduced (<xref rid="b30-mmr-13-04-3639" ref-type="bibr">30</xref>). Lower mortality, and reduced inflammatory cell infiltration and injury of the intestinal tract in ICAM-1-deficient mice indicates that ICAM-1 is important in the development of enteritis (<xref rid="b31-mmr-13-04-3639" ref-type="bibr">31</xref>). The present data demonstrated that administration of glycyrrhizic acid significantly reduces ICAM-1 mRNA expression in MTX-induced enteritis rat. In addition, Wang <italic>et al</italic> (<xref rid="b21-mmr-13-04-3639" ref-type="bibr">21</xref>) suggested that glycyrrhizic acid attenuates glycative stress in the kidneys of diabetic mice through inhibition of monocyte chemotactic protein-1 and ICAM-1. Together, these results suggest that the anti-inflammatory activity of glycyrrhizic acid during enteritis may be partially mediated through inhibition of ICAM-1.</p>
<p>IFNs are a group of broad-spectrum anti-viral glycoproteins secreted by cells upon attack by viruses. IFN-&#x003B3;, which is secreted by lymphocytes, is involved in the expression of histocompatibility antigen and immune adjustment (<xref rid="b32-mmr-13-04-3639" ref-type="bibr">32</xref>). It is understood that the interaction between IFN-&#x003B3; and TNF-&#x003B1; can change the structure of intestinal epithelial cells and the barrier function, leading to increased intestine permeability. Increased expression of IFN-&#x003B3; is commonly observed in enteritis (<xref rid="b4-mmr-13-04-3639" ref-type="bibr">4</xref>,<xref rid="b32-mmr-13-04-3639" ref-type="bibr">32</xref>). In agreement with this, the present study demonstrated that glycyrrhizic acid could reduced MTX-induced NF-&#x003BA;B-p65 and IFN-&#x003B3; protein expression in rat enteritis. Feng <italic>et al</italic> (<xref rid="b33-mmr-13-04-3639" ref-type="bibr">33</xref>) demonstrated that glycyrrhizic acid protects against advanced glycation end-product (AGE)-induced endothelial dysfunction via inhibition of the receptor for AGE/NF-&#x003BA;B signaling pathway. Wu <italic>et al</italic> (<xref rid="b34-mmr-13-04-3639" ref-type="bibr">34</xref>) reported that glycyrrhizic acid significantly reduced inflammatory via IFN-&#x003B3;. This indicates that inhibition of the IFN-&#x003B3; signaling pathway may be associated with the anti-inflammatory effects of glycyrrhizic acid in enteritis.</p>
<p>Enteritis affects intestinal mucosa microcirculation, inflammatory cell infiltration, blood hypercoagulability, microthrombus and inflammatory polyp formation, leading to hypoxia and ischemia of the intestinal mucosa microcirculation, and a severe imbalance of cell factors, including the IL and TNF-&#x003B1; superfamilies, colony stimulating factor, chemokines and growth factors (<xref rid="b35-mmr-13-04-3639" ref-type="bibr">35</xref>). iNOS levels are increased during enteritis and are positively associated with the disease activity index, which reflects the degree of inflammation. iNOS catalyzes the production of NO, which is associated with the pathophysiology of inflammatory diseases and cancer (<xref rid="b5-mmr-13-04-3639" ref-type="bibr">5</xref>,<xref rid="b32-mmr-13-04-3639" ref-type="bibr">32</xref>). The results of the current study demonstrated that glycyrrhizic acid significantly inhibits MTX-induced caspase-3 activity and iNOS expression in enteritis. This suggests that glycyrrhizic acid has anti-apoptotic effects and suppresses iNOS expression during enteritis.</p>
<p>COX-2 is an inducible enzyme that is expressed at low levels in the majority of tissues under normal conditions (<xref rid="b36-mmr-13-04-3639" ref-type="bibr">36</xref>). When induced by pro-infammatory cytokines, several cell types, including endothelial cells, vascular smooth muscle cells, mononuclear macrophages and fibroblasts, rapidly increase the expression of COX-2 to 8 to 10-fold the normal level (<xref rid="b37-mmr-13-04-3639" ref-type="bibr">37</xref>). Increased COX-2 leads to the production and accumulation of prostaglandin inflammatory factors, promoting inflammatory responses and tissue damage (<xref rid="b36-mmr-13-04-3639" ref-type="bibr">36</xref>). Overexpression of COX-2 promotes cell proliferation, inhibits apoptosis and inhibits the immune response, leading to dysregulation of the balance between proliferation and apoptosis (<xref rid="b36-mmr-13-04-3639" ref-type="bibr">36</xref>,<xref rid="b37-mmr-13-04-3639" ref-type="bibr">37</xref>). The present study demonstrated that glycyrrhizic acid significantly reduces MTX-induced COX-2 activity in enteritis. Bhattacharjee <italic>et al</italic> (<xref rid="b28-mmr-13-04-3639" ref-type="bibr">28</xref>) also demonstrated that glycyrrhizic acid suppressed COX-2 during <italic>L. donovani</italic> infection. Additionally, Cherng <italic>et al</italic> (<xref rid="b38-mmr-13-04-3639" ref-type="bibr">38</xref>) reported that glycyrrhizic acid inhibited NF-&#x003BA;B and COX-2 expression, prevented DNA damage and facilitated DNA repair.</p>
<p>As an important member of the MAPK signaling pathway, p38MAPK is widely expressed in a variety of tissues (<xref rid="b39-mmr-13-04-3639" ref-type="bibr">39</xref>). Under normal physiological conditions, p38MAPK typically exhibits low activity and is activated upon stimulation by growth factors, lipopolysaccharides and stress (<xref rid="b40-mmr-13-04-3639" ref-type="bibr">40</xref>). Previous research has demonstrated that when cells are stimulated by the aforementioned factors, p38MAPK regulates the inflammatory response via the production of pro-infammatory cytokines, including TNF-&#x003B1;, IL-1, IL-6 and IL-8, as well as anti-inflammatory cytokines, such as IL-10 (<xref rid="b40-mmr-13-04-3639" ref-type="bibr">40</xref>,<xref rid="b41-mmr-13-04-3639" ref-type="bibr">41</xref>). As a result, p38MAPK influences the balance between pro- and anti-inflammatory cytokines, thereby influencing processes that cause enteritis (<xref rid="b42-mmr-13-04-3639" ref-type="bibr">42</xref>). The current study demonstrated that glycyrrhizic acid significantly downregulates the protein expression levels of p38MAPK in MTX-induced enteritis. Additionally, several other previous studies demonstrated that glycyrrhizic acid attenuates glycative stress in the kidneys of diabetic mice through suppression of NF-&#x003BA;B and p-p38MAPK (<xref rid="b21-mmr-13-04-3639" ref-type="bibr">21</xref>,<xref rid="b43-mmr-13-04-3639" ref-type="bibr">43</xref>). These data support the hypothesis that the anti-inflammatory effects of glycyrrhizic acid may be associated with p38MAPK signaling.</p>
<p>In conclusion, the results of the current study demonstrate that glycyrrhizic acid exerts a protective effect during MTX-induced enteritis and may be useful as a therapeutic agent for digestive tract diseases. Furthermore, the protective effect of glycyrrhizic acid is associated with anti-inflammatory and anti-apoptotic pathways, suppression of ICAM-1, IFN-&#x003B3;, iNOS and COX-2 expression, and downregulation of the p38MAPK pathway. Therefore, glycyrrhizic acid may be a novel therapeutic approach for the treatment of enteritis.</p></sec></body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-mmr-13-04-3639"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Naito</surname><given-names>Y</given-names></name><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Takaoka</surname><given-names>M</given-names></name><name><surname>Oya-Ito</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Hirai</surname><given-names>Y</given-names></name><name><surname>Mizushima</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Kamada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Hemopexin is upregulated in rat intestinal mucosa injured by indomethacin</article-title><source>J Gastroenterol Hepatol</source><volume>27</volume><issue>Suppl 3</issue><fpage>70</fpage><lpage>75</lpage><year>2012</year><pub-id pub-id-type="doi">10.1111/j.1440-1746.2012.07076.x</pub-id><pub-id pub-id-type="pmid">22486875</pub-id></element-citation></ref>
<ref id="b2-mmr-13-04-3639"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>MJ</given-names></name><name><surname>Brian</surname><given-names>H</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name></person-group><article-title>A comparative analysis of ethnomedicinal practices for treating gastrointestinal disorders used by communities living in three national parks (Korea)</article-title><source>Evid Based Complement Alternat Med</source><volume>2014</volume><fpage>108037</fpage><year>2014</year><pub-id pub-id-type="doi">10.1155/2014/108037</pub-id><pub-id pub-id-type="pmid">25202330</pub-id><pub-id pub-id-type="pmcid">4150413</pub-id></element-citation></ref>
<ref id="b3-mmr-13-04-3639"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoidis</surname><given-names>CN</given-names></name><name><surname>Misiakos</surname><given-names>EP</given-names></name><name><surname>Patapis</surname><given-names>P</given-names></name><name><surname>Fotiadis</surname><given-names>CI</given-names></name><name><surname>Spyropoulos</surname><given-names>BG</given-names></name></person-group><article-title>Potential benefits of pro- and prebiotics on intestinal mucosal immunity and intestinal barrier in short bowel syndrome</article-title><source>Nutr Res Rev</source><volume>24</volume><fpage>21</fpage><lpage>30</lpage><year>2011</year><pub-id pub-id-type="doi">10.1017/S0954422410000260</pub-id></element-citation></ref>
<ref id="b4-mmr-13-04-3639"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbroucke</surname><given-names>RE</given-names></name><name><surname>Dejonckheere</surname><given-names>E</given-names></name><name><surname>Van Hauwermeiren</surname><given-names>F</given-names></name><name><surname>Lodens</surname><given-names>S</given-names></name><name><surname>De Rycke</surname><given-names>R</given-names></name><name><surname>Van Wonterghem</surname><given-names>E</given-names></name><name><surname>Staes</surname><given-names>A</given-names></name><name><surname>Gevaert</surname><given-names>K</given-names></name><name><surname>L&#x000F3;pez-Otin</surname><given-names>C</given-names></name><name><surname>Libert</surname><given-names>C</given-names></name></person-group><article-title>Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF</article-title><source>EMBO Mol Med</source><volume>5</volume><fpage>932</fpage><lpage>948</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/emmm.201202100</pub-id><pub-id pub-id-type="pmid">23723167</pub-id><pub-id pub-id-type="pmcid">3721470</pub-id></element-citation></ref>
<ref id="b5-mmr-13-04-3639"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XP</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>QL</given-names></name><name><surname>Chen</surname><given-names>HQ</given-names></name></person-group><article-title>Mechanism of acute pancreatitis complicated with injury of intestinal mucosa barrier</article-title><source>J Zhejiang Univ Sci B</source><volume>8</volume><fpage>888</fpage><lpage>895</lpage><year>2007</year><pub-id pub-id-type="doi">10.1631/jzus.2007.B0888</pub-id></element-citation></ref>
<ref id="b6-mmr-13-04-3639"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JE</given-names></name><name><surname>Snook</surname><given-names>AE</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Stoecker</surname><given-names>BA</given-names></name><name><surname>Kim</surname><given-names>GW</given-names></name><name><surname>Magee</surname><given-names>MS</given-names></name><name><surname>Garcia</surname><given-names>AV</given-names></name><name><surname>Valentino</surname><given-names>MA</given-names></name><name><surname>Hyslop</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>S</given-names></name><name><surname>Waldman</surname><given-names>SA</given-names></name></person-group><article-title>GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity</article-title><source>PLoS One</source><volume>7</volume><fpage>e31686</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0031686</pub-id><pub-id pub-id-type="pmid">22384056</pub-id><pub-id pub-id-type="pmcid">3284579</pub-id></element-citation></ref>
<ref id="b7-mmr-13-04-3639"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetrano</surname><given-names>S</given-names></name><name><surname>Ploplis</surname><given-names>VA</given-names></name><name><surname>Sala</surname><given-names>E</given-names></name><name><surname>Sandoval-Cooper</surname><given-names>M</given-names></name><name><surname>Donahue</surname><given-names>DL</given-names></name><name><surname>Correale</surname><given-names>C</given-names></name><name><surname>Arena</surname><given-names>V</given-names></name><name><surname>Spinelli</surname><given-names>A</given-names></name><name><surname>Repici</surname><given-names>A</given-names></name><name><surname>Malesci</surname><given-names>A</given-names></name><etal/></person-group><article-title>Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation</article-title><source>Proc Natl Acad Sci USA</source><volume>108</volume><fpage>19830</fpage><lpage>19835</lpage><year>2011</year><pub-id pub-id-type="doi">10.1073/pnas.1107140108</pub-id><pub-id pub-id-type="pmid">22109555</pub-id><pub-id pub-id-type="pmcid">3241765</pub-id></element-citation></ref>
<ref id="b8-mmr-13-04-3639"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talukder</surname><given-names>JR</given-names></name><name><surname>Boyd</surname><given-names>B</given-names></name><name><surname>Griffin</surname><given-names>A</given-names></name><name><surname>Jaima</surname><given-names>A</given-names></name><name><surname>Rajendran</surname><given-names>VM</given-names></name></person-group><article-title>Inflammatory cytokine TNF-&#x003B1; inhibits Na(+)-glutamine cotransport in intestinal epithelial cells</article-title><source>Can J Physiol Pharmacol</source><volume>91</volume><fpage>275</fpage><lpage>284</lpage><year>2013</year><pub-id pub-id-type="doi">10.1139/cjpp-2011-0488</pub-id><pub-id pub-id-type="pmid">23627839</pub-id></element-citation></ref>
<ref id="b9-mmr-13-04-3639"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Review of pharmacological effects of Glycyrrhiza radix and its bioactive compounds</article-title><source>Zhongguo Zhong Yao Za Zhi</source><volume>34</volume><fpage>2695</fpage><lpage>2700</lpage><year>2009</year><comment>In Chinese</comment></element-citation></ref>
<ref id="b10-mmr-13-04-3639"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asl</surname><given-names>MN</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H</given-names></name></person-group><article-title>Review of pharmacological effects of Glycyrrhiza sp and its bioactive compounds</article-title><source>Phytother Res</source><volume>22</volume><fpage>709</fpage><lpage>724</lpage><year>2008</year><pub-id pub-id-type="doi">10.1002/ptr.2362</pub-id><pub-id pub-id-type="pmid">18446848</pub-id></element-citation></ref>
<ref id="b11-mmr-13-04-3639"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isbrucker</surname><given-names>RA</given-names></name><name><surname>Burdock</surname><given-names>GA</given-names></name></person-group><article-title>Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin</article-title><source>Regul Toxicol Pharmacol</source><volume>46</volume><fpage>167</fpage><lpage>192</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.yrtph.2006.06.002</pub-id><pub-id pub-id-type="pmid">16884839</pub-id></element-citation></ref>
<ref id="b12-mmr-13-04-3639"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>EM</given-names></name><name><surname>Zhou</surname><given-names>HY</given-names></name><name><surname>Guo</surname><given-names>LY</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Merfort</surname><given-names>I</given-names></name><name><surname>Kang</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Anti-inflammatory effects of glycyrol isolated from Glycyrrhiza uralensis in LPS-stimulated RAW264.7 macrophages</article-title><source>Int Immunopharmacol</source><volume>8</volume><fpage>1524</fpage><lpage>1532</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.intimp.2008.06.008</pub-id><pub-id pub-id-type="pmid">18621150</pub-id></element-citation></ref>
<ref id="b13-mmr-13-04-3639"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschelli</surname><given-names>S</given-names></name><name><surname>Pesce</surname><given-names>M</given-names></name><name><surname>Vinciguerra</surname><given-names>I</given-names></name><name><surname>Ferrone</surname><given-names>A</given-names></name><name><surname>Riccioni</surname><given-names>G</given-names></name><name><surname>Patruno</surname><given-names>A</given-names></name><name><surname>Grilli</surname><given-names>A</given-names></name><name><surname>Felaco</surname><given-names>M</given-names></name><name><surname>Speranza</surname><given-names>L</given-names></name></person-group><article-title>Licocalchone-C extracted from Glycyrrhiza glabra inhibits lipopolysaccharide-interferon-&#x003B3; inflammation by improving antioxidant conditions and regulating inducible nitric oxide synthase expression</article-title><source>Molecules</source><volume>16</volume><fpage>5720</fpage><lpage>5734</lpage><year>2011</year><pub-id pub-id-type="doi">10.3390/molecules16075720</pub-id><pub-id pub-id-type="pmid">21734629</pub-id></element-citation></ref>
<ref id="b14-mmr-13-04-3639"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Ying</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>G</given-names></name></person-group><article-title>Identification of nuclear factor-kappaB inhibitors in the folk herb Rhizoma Menispermi via bioactivity-based ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry analysis</article-title><source>BMC Complement Altern Med</source><volume>14</volume><fpage>356</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1472-6882-14-356</pub-id></element-citation></ref>
<ref id="b15-mmr-13-04-3639"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi Wi</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Shim</surname><given-names>JH</given-names></name><name><surname>Chun</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name></person-group><article-title>Ubiquitination of ECSIT is crucial for the activation of p65/p50 NF-kappaBs in Toll-like receptor 4 signaling</article-title><source>Mol Biol Cell</source><volume>26</volume><fpage>151</fpage><lpage>160</lpage><year>2015</year><pub-id pub-id-type="doi">10.1091/mbc.E14-08-1277</pub-id><pub-id pub-id-type="pmcid">4279226</pub-id></element-citation></ref>
<ref id="b16-mmr-13-04-3639"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Shu</surname><given-names>HB</given-names></name></person-group><article-title>The E3 ubiquitin ligase MARCH8 negatively regulates IL-1&#x003B2;-induced NF-&#x003BA;B activation by targeting the IL1RAP coreceptor for ubiquitination and degradation</article-title><source>Proc Natl Acad Sci USA</source><volume>109</volume><fpage>14128</fpage><lpage>14133</lpage><year>2012</year><pub-id pub-id-type="doi">10.1073/pnas.1205246109</pub-id></element-citation></ref>
<ref id="b17-mmr-13-04-3639"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Ni</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Ginsenoside-Rg1 enhances angio-genesis and ameliorates ventricular remodeling in a rat model of myocardial infarction</article-title><source>J Mol Med (Berl)</source><volume>89</volume><fpage>363</fpage><lpage>375</lpage><year>2011</year><pub-id pub-id-type="doi">10.1007/s00109-011-0723-9</pub-id></element-citation></ref>
<ref id="b18-mmr-13-04-3639"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KR</given-names></name><name><surname>Nam</surname><given-names>D</given-names></name><name><surname>Yun</surname><given-names>HM</given-names></name><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Jang</surname><given-names>HJ</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><name><surname>Cho</surname><given-names>SK</given-names></name><name><surname>Ahn</surname><given-names>KS</given-names></name></person-group><article-title>&#x003B2;-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation</article-title><source>Cancer Lett</source><volume>312</volume><fpage>178</fpage><lpage>188</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.canlet.2011.08.001</pub-id><pub-id pub-id-type="pmid">21924548</pub-id></element-citation></ref>
<ref id="b19-mmr-13-04-3639"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>CK</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Ha</surname><given-names>KS</given-names></name><name><surname>Won</surname><given-names>MH</given-names></name><name><surname>Kwon</surname><given-names>YG</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name></person-group><article-title>The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways</article-title><source>Mol Pharmacol</source><volume>78</volume><fpage>142</fpage><lpage>150</lpage><year>2010</year><pub-id pub-id-type="doi">10.1124/mol.110.063586</pub-id><pub-id pub-id-type="pmid">20406854</pub-id></element-citation></ref>
<ref id="b20-mmr-13-04-3639"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Institute of Laboratory Animal Resources (US)</collab><collab>Committee on Care Use of Laboratory Animals National Institutes of Health (US)</collab><collab>Division of Research Resources</collab></person-group><source>Guide for the care and use of laboratory animals</source><edition>8th edition</edition><publisher-name>National Academies Press</publisher-name><publisher-loc>Washington, DC</publisher-loc><year>2011</year></element-citation></ref>
<ref id="b21-mmr-13-04-3639"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZH</given-names></name><name><surname>Hsieh</surname><given-names>CH</given-names></name><name><surname>Liu</surname><given-names>WH</given-names></name><name><surname>Yin</surname><given-names>MC</given-names></name></person-group><article-title>Glycyrrhizic acid attenuated glycative stress in kidney of diabetic mice through enhancing glyoxalase pathway</article-title><source>Mol Nutr Food Res</source><volume>58</volume><fpage>1426</fpage><lpage>1435</lpage><year>2014</year><pub-id pub-id-type="doi">10.1002/mnfr.201300910</pub-id><pub-id pub-id-type="pmid">24585461</pub-id></element-citation></ref>
<ref id="b22-mmr-13-04-3639"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>AQ</given-names></name><name><surname>Lateef</surname><given-names>A</given-names></name><name><surname>Rehman</surname><given-names>MU</given-names></name><name><surname>Tahir</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>F</given-names></name><name><surname>Hamiza</surname><given-names>OO</given-names></name><name><surname>Sultana</surname><given-names>S</given-names></name></person-group><article-title>Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyper-proliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats</article-title><source>PLoS One</source><volume>8</volume><fpage>e56020</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0056020</pub-id></element-citation></ref>
<ref id="b23-mmr-13-04-3639"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZX</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Hua</surname><given-names>YP</given-names></name><name><surname>Huang</surname><given-names>WQ</given-names></name><name><surname>Deng</surname><given-names>LH</given-names></name><name><surname>Liu</surname><given-names>KX</given-names></name></person-group><article-title>Dexmedetomidine reduces intestinal and hepatic injury after hepatectomy with inflow occlusion under general anaesthesia: A randomized controlled trial</article-title><source>Br J Anaesth</source><volume>112</volume><fpage>1055</fpage><lpage>1064</lpage><year>2014</year><pub-id pub-id-type="doi">10.1093/bja/aeu132</pub-id><pub-id pub-id-type="pmid">24771805</pub-id></element-citation></ref>
<ref id="b24-mmr-13-04-3639"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-tie quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></element-citation></ref>
<ref id="b25-mmr-13-04-3639"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>SM</given-names></name><name><surname>Wolfinbarger</surname><given-names>JB</given-names></name><name><surname>Bloom</surname><given-names>ME</given-names></name></person-group><article-title>Caspase activation is required for permissive replication of Aleutian mink disease parvovirus in vitro</article-title><source>Virology</source><volume>292</volume><fpage>224</fpage><lpage>234</lpage><year>2002</year><pub-id pub-id-type="doi">10.1006/viro.2001.1238</pub-id><pub-id pub-id-type="pmid">11878925</pub-id></element-citation></ref>
<ref id="b26-mmr-13-04-3639"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>S</given-names></name><name><surname>Mencarelli</surname><given-names>A</given-names></name><name><surname>Chini</surname><given-names>MG</given-names></name><name><surname>Distrutti</surname><given-names>E</given-names></name><name><surname>Renga</surname><given-names>B</given-names></name><name><surname>Bifulco</surname><given-names>G</given-names></name><name><surname>Baldelli</surname><given-names>F</given-names></name><name><surname>Donini</surname><given-names>A</given-names></name><name><surname>Fiorucci</surname><given-names>S</given-names></name></person-group><article-title>The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis</article-title><source>PLoS One</source><volume>6</volume><fpage>e25637</fpage><year>2011</year><pub-id pub-id-type="doi">10.1371/journal.pone.0025637</pub-id><pub-id pub-id-type="pmid">22046243</pub-id><pub-id pub-id-type="pmcid">3203117</pub-id></element-citation></ref>
<ref id="b27-mmr-13-04-3639"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>JM</given-names></name><name><surname>Martinez</surname><given-names>GJ</given-names></name><name><surname>Nallaparaju</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name></person-group><article-title>Cutting edge: Regulation of intestinal inflammation and barrier function by IL-17C</article-title><source>J Immunol</source><volume>189</volume><fpage>4226</fpage><lpage>4230</lpage><year>2012</year><pub-id pub-id-type="doi">10.4049/jimmunol.1103014</pub-id><pub-id pub-id-type="pmid">23024280</pub-id><pub-id pub-id-type="pmcid">3478486</pub-id></element-citation></ref>
<ref id="b28-mmr-13-04-3639"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>S</given-names></name><name><surname>Bhattacharjee</surname><given-names>A</given-names></name><name><surname>Majumder</surname><given-names>S</given-names></name><name><surname>Majumdar</surname><given-names>SB</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name></person-group><article-title>Glycyrrhizic acid suppresses Cox-2-mediated anti-inflammatory responses during Leishmania donovani infection</article-title><source>J Antimicrob Chemother</source><volume>67</volume><fpage>1905</fpage><lpage>1914</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/jac/dks159</pub-id><pub-id pub-id-type="pmid">22589456</pub-id></element-citation></ref>
<ref id="b29-mmr-13-04-3639"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orazizadeh</surname><given-names>M</given-names></name><name><surname>Fakhredini</surname><given-names>F</given-names></name><name><surname>Mansouri</surname><given-names>E</given-names></name><name><surname>Khorsandi</surname><given-names>L</given-names></name></person-group><article-title>Effect of glycyrrhizic acid on titanium dioxide nanoparticles-induced hepatotoxicity in rats</article-title><source>Chem Biol Interact</source><volume>220</volume><fpage>214</fpage><lpage>221</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.cbi.2014.07.001</pub-id><pub-id pub-id-type="pmid">25016076</pub-id></element-citation></ref>
<ref id="b30-mmr-13-04-3639"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>JD</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kozarek</surname><given-names>RA</given-names></name></person-group><article-title>A case of fatal idiopathic enteritis and multiple opportunistic infections associated with dendritic cell deficiencies</article-title><source>J Gastrointestin Liver Dis</source><volume>22</volume><fpage>87</fpage><lpage>91</lpage><year>2013</year><pub-id pub-id-type="pmid">23539396</pub-id><pub-id pub-id-type="pmcid">4366003</pub-id></element-citation></ref>
<ref id="b31-mmr-13-04-3639"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miner</surname><given-names>P</given-names></name><name><surname>Wedel</surname><given-names>M</given-names></name><name><surname>Bane</surname><given-names>B</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name></person-group><article-title>An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis</article-title><source>Aliment Pharmacol Ther</source><volume>19</volume><fpage>281</fpage><lpage>286</lpage><year>2004</year><pub-id pub-id-type="doi">10.1111/j.1365-2036.2004.01863.x</pub-id><pub-id pub-id-type="pmid">14984374</pub-id></element-citation></ref>
<ref id="b32-mmr-13-04-3639"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CF</given-names></name><name><surname>Wu</surname><given-names>TC</given-names></name><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Lo</surname><given-names>WT</given-names></name><name><surname>Hwang</surname><given-names>KS</given-names></name><name><surname>Hsu</surname><given-names>ML</given-names></name><name><surname>Peng</surname><given-names>HJ</given-names></name></person-group><article-title>Sublingual vaccination with sonicated Salmonella proteins and mucosal adjuvant induces mucosal and systemic immunity and protects mice from lethal enteritis</article-title><source>APMIS</source><volume>119</volume><fpage>468</fpage><lpage>478</lpage><year>2011</year><pub-id pub-id-type="doi">10.1111/j.1600-0463.2011.02761.x</pub-id><pub-id pub-id-type="pmid">21635554</pub-id></element-citation></ref>
<ref id="b33-mmr-13-04-3639"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>MM</given-names></name><name><surname>Zhang</surname><given-names>MH</given-names></name><name><surname>Wang</surname><given-names>RS</given-names></name><name><surname>Tan</surname><given-names>XB</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>SM</given-names></name><name><surname>Jia</surname><given-names>XB</given-names></name><name><surname>Hu</surname><given-names>SY</given-names></name></person-group><article-title>Protection of glycyrrhizic acid against AGEs-induced endothelial dysfunction through inhibiting RAGE/NF-&#x003BA;B pathway activation in human umbilical vein endothelial cells</article-title><source>J Ethnopharmacol</source><volume>148</volume><fpage>27</fpage><lpage>36</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.jep.2013.03.035</pub-id><pub-id pub-id-type="pmid">23528363</pub-id></element-citation></ref>
<ref id="b34-mmr-13-04-3639"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><article-title>Therapeutic effects of glycyrrhizic acid on asthma airway inflammation in mice and its mechanism</article-title><source>Zhonghua Yi Xue Za Zhi</source><volume>94</volume><fpage>3338</fpage><lpage>3344</lpage><year>2014</year><comment>In Chinese</comment></element-citation></ref>
<ref id="b35-mmr-13-04-3639"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorge</surname><given-names>E</given-names></name><name><surname>Vergara</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>MT</given-names></name></person-group><article-title>Ileal inducible nitric oxide synthase mRNA expression in response to stress is modified in Sprague-Dawley rats exposed to a previous intestinal inflammation</article-title><source>Stress</source><volume>15</volume><fpage>62</fpage><lpage>73</lpage><year>2012</year><pub-id pub-id-type="doi">10.3109/10253890.2011.582655</pub-id></element-citation></ref>
<ref id="b36-mmr-13-04-3639"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Rong</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name></person-group><article-title>Renal cell carcinoma may evade the immune system by converting CD4<sup>+</sup>Foxp3<sup>&#x02212;</sup> T cells into CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells: Role of tumor COX-2-derived PGE2</article-title><source>Mol Med Rep</source><volume>3</volume><fpage>959</fpage><lpage>963</lpage><year>2010</year></element-citation></ref>
<ref id="b37-mmr-13-04-3639"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name></person-group><article-title>Anti-inflammatory function of Withangulatin A by targeted inhibiting COX-2 expression via MAPK and NF-kappaB pathways</article-title><source>J Cell Biochem</source><volume>109</volume><fpage>532</fpage><lpage>541</lpage><year>2010</year></element-citation></ref>
<ref id="b38-mmr-13-04-3639"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherng</surname><given-names>JM</given-names></name><name><surname>Tsai</surname><given-names>KD</given-names></name><name><surname>Yu</surname><given-names>YW</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name></person-group><article-title>Molecular mechanisms underlying chemopreventive activities of glycyrrhizic acid against UVB-radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis</article-title><source>Radiat Res</source><volume>176</volume><fpage>177</fpage><lpage>186</lpage><year>2011</year><pub-id pub-id-type="doi">10.1667/RR2510.1</pub-id><pub-id pub-id-type="pmid">21545294</pub-id></element-citation></ref>
<ref id="b39-mmr-13-04-3639"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>S</given-names></name><name><surname>Ai</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Lyu</surname><given-names>Q</given-names></name><name><surname>Kuang</surname><given-names>Y</given-names></name></person-group><article-title>The M2 polarization of macrophage induced by fractalkine in the endometriotic milieu enhances invasiveness of endometrial stromal cells</article-title><source>Int J Clin Exp Pathol</source><volume>7</volume><fpage>194</fpage><lpage>203</lpage><year>2014</year><pub-id pub-id-type="pmid">24427339</pub-id><pub-id pub-id-type="pmcid">3885473</pub-id></element-citation></ref>
<ref id="b40-mmr-13-04-3639"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name></person-group><article-title>Protective effects of protocatechuic acid on acute lung injury induced by lipopolysaccharide in mice via p38MAPK and NF-&#x003BA;B signal pathways</article-title><source>Int Immunopharmacol</source><volume>26</volume><fpage>229</fpage><lpage>236</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.intimp.2015.03.031</pub-id><pub-id pub-id-type="pmid">25841318</pub-id></element-citation></ref>
<ref id="b41-mmr-13-04-3639"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bredeson</surname><given-names>S</given-names></name><name><surname>Papaconstantinou</surname><given-names>J</given-names></name><name><surname>Deford</surname><given-names>JH</given-names></name><name><surname>Kechichian</surname><given-names>T</given-names></name><name><surname>Syed</surname><given-names>A</given-names></name><name><surname>Saade</surname><given-names>GR</given-names></name><name><surname>Menon</surname><given-names>R</given-names></name></person-group><article-title>HMGB1 promotes a p38MAPK associated non-infectious inflammatory response pathway in human fetal membranes</article-title><source>PLoS One</source><volume>9</volume><fpage>e113799</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0113799</pub-id><pub-id pub-id-type="pmid">25469638</pub-id><pub-id pub-id-type="pmcid">4254744</pub-id></element-citation></ref>
<ref id="b42-mmr-13-04-3639"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiho</surname><given-names>H</given-names></name><name><surname>Tokita</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name><name><surname>Nishiyama</surname><given-names>M</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Tsuchiya</surname><given-names>K</given-names></name><name><surname>Ohbuchi</surname><given-names>K</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Ihara</surname><given-names>E</given-names></name><etal/></person-group><article-title>Involvement of interleukin-17A-induced hypercontractility of intestinal smooth muscle cells in persistent gut motor dysfunction</article-title><source>PLoS One</source><volume>9</volume><fpage>e92960</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0092960</pub-id><pub-id pub-id-type="pmid">24796324</pub-id><pub-id pub-id-type="pmcid">4010403</pub-id></element-citation></ref>
<ref id="b43-mmr-13-04-3639"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojcik</surname><given-names>M</given-names></name><name><surname>Zieleniak</surname><given-names>A</given-names></name><name><surname>Zurawska-Klis</surname><given-names>M</given-names></name><name><surname>Cypryk</surname><given-names>K</given-names></name><name><surname>Wozniak</surname><given-names>LA</given-names></name></person-group><article-title>Increased expression of immune-related genes in leukocytes of patients with diagnosed gestational diabetes mellitus (GDM)</article-title><source>Exp Biol Med (Maywood)</source><year>2015</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-mmr-13-04-3639" position="float">
<label>Figure 1</label>
<caption>
<p>Chemical structure of glycyrrhizic acid.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g00.tif"/></fig>
<fig id="f2-mmr-13-04-3639" position="float">
<label>Figure 2</label>
<caption>
<p>Effect of glycyrrhizic acid on expression of inflammatory factors in enteritis. (A) TNF-&#x003B1;, (B) IL-1&#x003B2;, (C) IL-6 and (D) IL-10 levels were measured using enzyme-linked immunosorbent assay in control, MTX-induced model and glycyrrhizic acid groups. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. TNF-&#x003B1;, tumor necrosis factor-&#x003B1;; IL, interleukin; MTX, methotrexate.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g01.jpg"/></fig>
<fig id="f3-mmr-13-04-3639" position="float">
<label>Figure 3</label>
<caption>
<p>Effect of glycyrrhizic acid on D-lactate and DAO in rat enteritis. (A) D-lactate and (B) DAO were measured in control, MTX-induced model and glycyrrhizic acid groups. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. MTX, methotrexate; DOA, diamine oxidase.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g02.jpg"/></fig>
<fig id="f4-mmr-13-04-3639" position="float">
<label>Figure 4</label>
<caption>
<p>Glycyrrhizic acid prevents ICAM-1 expression in MTX-induced enteritis. ICAM-1 expression was measured in control, MTX-induced model and glycyrrhizic acid groups using reverse transcription-quantiative poly-merase chain reaction analysis. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. the control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. ICAM-1, intercellular adhesion molecule 1; MTX, methotrexate.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g03.jpg"/></fig>
<fig id="f5-mmr-13-04-3639" position="float">
<label>Figure 5</label>
<caption>
<p>Glycyrrhizic acid prevents NF-&#x003BA;B-p65 expression in rat enteritis. (A) NF-&#x003BA;B-p65 expression was measured by western blotting assays and (B) statistical analysis of NF-&#x003BA;B-p65 protein expression was performed using protein from control, MTX-induced model and glycyrrhizic acid groups. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. NF-&#x003BA;B, nuclear factor-&#x003BA;B; MTX, methotrexate.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g04.jpg"/></fig>
<fig id="f6-mmr-13-04-3639" position="float">
<label>Figure 6</label>
<caption>
<p>Glycyrrhizic acid reduces IFN-&#x003B3; levels in enteritis rat. IFN-&#x003B3; was measured in control, MTX-induced model and glycyrrhizic acid groups. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. IFN-&#x003B3;, interferon-&#x003B3;; MTX, methotrexate.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g05.jpg"/></fig>
<fig id="f7-mmr-13-04-3639" position="float">
<label>Figure 7</label>
<caption>
<p>Glycyrrhizic acid prevents caspase-3 activity in enteritis rat. Caspase-3 activity was measured in tissue sample from control, MTX-induced model and glycyrrhizic acid groups. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. MTX, methotrexate.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g06.jpg"/></fig>
<fig id="f8-mmr-13-04-3639" position="float">
<label>Figure 8</label>
<caption>
<p>Glycyrrhizic acid prevents iNOS expression in rat enteritis. (A) Western blotting was performed to measure iNOS protein expression and (B) statistically analyzed in samples from control, MTX-induced model and glycyrrhizic acid groups. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. iNOS, nitric oxide synthase; MTX, methotrexate.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g07.jpg"/></fig>
<fig id="f9-mmr-13-04-3639" position="float">
<label>Figure 9</label>
<caption>
<p>Glycyrrhizic acid prevents COX-2 activity in rat enteritis. COX-2 activity was measured in samples from control, MTX-induced model and glycyrrhizic acid groups. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. COX-2, cyclooxygenase-2; MTX, methotrexate.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g08.jpg"/></fig>
<fig id="f10-mmr-13-04-3639" position="float">
<label>Figure 10</label>
<caption>
<p>Expression and phosphorylation of p38 in enteritis rat. (A) p- and total p38 expression were measured in protein samples from control, MTX-induced model and glycyrrhizic acid groups by western blotting and (B) quantified using statistical analysis. <sup>&#x0002A;&#x0002A;</sup>P&lt;0.01 vs. control group; <sup>##</sup>P&lt;0.01 vs. the MTX group. p-p38, phosphorylated-p38 mitogen-activated protein kinase; MTX, methotrexate.</p></caption>
<graphic xlink:href="MMR-13-04-3639-g09.jpg"/></fig></floats-group></article>
